Gilead hit with antitrust suit over HIV drugs
Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Breaking: EPO board to refer key issues in Broad appeal to higher panel
The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.
EPO appeals board weighs-up Broad’s CRISPR claims
The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.
Jennewein takes on Nestlé over baby formula patents
German biotech Jennewein has accused Nestlé Nutrition of infringing patents covering a process of purifying human milk oligosaccharides to make its infant formula.
California mulls state generics brand
California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
Judge refuses to block pay-for-delay law pending appeal
A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Bayer begins $240m AI drug discovery project with Exscientia
Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Senju, Bausch settle eye drop litigation against Indian generics maker
Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.
Fed Circuit issues mixed Sensipar verdict for Amgen
In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.
Allergan agrees to pay $300m to end birth control litigation
Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.
